Huahai Pharmaceutical (600521.SH) subsidiary approved to conduct Phase I clinical trial for injection HB0043.

Zhtng Cijng APP News, Huahai Pharmaceutical (600521.SH) announced that its subsidiary, Shanghai Huao Tai Biological Pharmaceutical Co., Ltd. (hereinafter referred to as "Huao Tai"), recently obtained approval from the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) and the Health and Disability Ethics Committee (HDEC) to conduct phase I clinical trials of injection HB0043 in the local area.